跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
JN-2
首页
药物
JN-2
JN-2
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
NOVEL CORONAVIRUS PROTECTIVE NASAL SPRAY, AND PREPARATION AND USE THEREOF
EP 4678663 A1
申请人: SICHUAN CLOVER BIOPHARMACEUTICALS INC
优先权: 2023
CN
EP
US
WO
4 件公开
PROTEIN, ADENOVIRUS AND VACCINE AGAINST INFECTION OF SUBTYPE OF SARS-COV-2 OMICRON MUTANT STRAIN XBB
EP 4759833 A1
申请人: WESTVAC BIOPHARMA CO LTD
优先权: 2023
CN
EP
WO
3 件公开
RECOMBINANT PROTEIN VACCINE FOR PREVENTING AND TREATING SARS-COV-2 VARIANTS JN.1, BA.2.86, AND XBB LINEAGES, DRUG FOR COMBINED USE, AND USE
WO 2025189658 A1
申请人: WESTVAC BIOPHARMA CO LTD
优先权: 2024
CN
WO
3 件公开
MULTISPECIFIC ANTIBODY
WO 2025214462 A1
申请人: UNIV FUDAN
优先权: 2024
CN
WO
2 件公开
T cell immunodominance epitope peptide of SARS-CoV-2 nucleocapsid protein mutation site and application of T cell immunodominance epitope peptide
CN 120682326 A
申请人: THE 8TH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV SHENZHEN FUTIAN
优先权: 2025
CN
2 件公开
Ankara vaccinia virus genetic engineering vaccine for pig replication and respiration complex
CN 101209351 B
申请人: WUCHANG SHIPBUILDING IND CO
优先权: 2006
CN
RECOMBINANT PROTEIN VACCINE FOR PREVENTING AND TREATING SARS-COV-2 VARIANT JN.1, BA.2.86, AND XBB LINEAGES, COMBINATION DRUG AND USE
WO 2025189415 A1
申请人: WESTVAC BIOPHARMA CO LTD
优先权: 2024
WO
Neutralizing antibody of anti-Omicron mutant strain and application of neutralizing antibody
CN 118978588 A
申请人: UNIV SUN YAT SEN
优先权: 2024
CN
Recombinant novel coronavirus Omicron variant RBD trimer antigen, immunogenic composition containing same and application of recombinant novel coronavirus Omicron variant RBD trimer antigen
CN 119219790 A
申请人: INST MICROBIOLOGY CAS
优先权: 2024
CN
New coronavirus recombinant trimer antigen composition and application thereof
CN 119192400 A
申请人: INST MICROBIOLOGY CAS
优先权: 2024
CN
第 1 / 2 页
上一页
下一页
药物
反馈